Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 30

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Hereditary neuropathic amyloidosis

Recruiting

Long-Term Safety and Efficacy Study of Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

InvestigationalNo placebo
Countries:CyprusCyprus
  • Participants:18–64 years · 65+ years
  • Substances:Eplontersen
  • Sponsor:Ionis Pharmaceuticals Inc.

Type 1 diabetes mellitus

Recruiting

Study on Sotagliflozin for Slowing Kidney Disease in Type 1 Diabetes Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Sotagliflozin
  • Sponsor:Steno Diabetes Center Copenhagen

Toxic epidermal necrolysis+1

Recruiting

Study on Filgrastim for Patients with Severe Bullous Drug Eruptions: Lyell and Stevens-Johnson Syndromes

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Hospices Civils De Lyon

Polymyalgia rheumatica

Recruiting

Study on Leflunomide for Preventing Relapses in Patients with Polymyalgia Rheumatica During Steroid Reduction

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Leflunomide
  • Sponsor:Universitair Medisch Centrum Groningen

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Aplasia pure red cell

Recruiting

Study on Isatuximab for Treating Pure Red Cell Aplasia in Patients with Major ABO Mismatch After Stem Cell Transplantation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Isatuximab
  • Sponsor:Assistance Publique Hopitaux De Paris

Conjunctivitis allergic+3

Recruiting

Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allergen Extract From Dactylis Glomerata Pollen, Glutaraldehyde-Modified
  • Sponsor:Inmunotek S.L.

Systemic scleroderma+2

Recruiting

Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
  • Sponsor:Miltenyi Biomedicine GmbH

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Rituximab for Achieving Remission in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Amsterdam UMC Stichting

HIV infection

Recruiting

Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dolutegravir Sodium
  • Sponsor:Inserm

Crohn's disease

Recruiting

Study Comparing Azathioprine and Methotrexate with Adalimumab for Patients with Crohn's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

IgA nephropathy

Recruiting

Study on Atrasentan for Patients with IgA Nephropathy at Risk of Kidney Function Loss

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zigakibart
  • Sponsor:Novartis Pharma AG

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.